ASH 2019 | Patient experience of CAR-T vs. HSCT
Surbhi Sidana
• 7 Dec 2019
Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, discusses the study evaluating the patient-reported quality of life (QoL) and symptom burden with CAR T-cell therapy compared with established forms of cellular therapy, such as autologous (auto-) and allogeneic (allo-) hematopoietic stem cell tranplantation (HSCT). This is one of the first studies comparing the patient experience of patients undergoing CAR-T vs. auto- and allo-HSCT. Generally, short-term QoL, including physical and functional well-being domains was better in the CAR-T group. In addition, Dr Sidana shares the next steps for the study. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
